Where now for anti-EGF receptor therapies in colorectal cancer?

Shaw, Paul ORCID: https://orcid.org/0000-0002-7467-0619 and Adams, Richard A. ORCID: https://orcid.org/0000-0003-3915-7243 2011. Where now for anti-EGF receptor therapies in colorectal cancer? Expert Review of Anticancer Therapy 11 (10) , pp. 1543-1553. 10.1586/era.11.143

Full text not available from this repository.

Abstract

Current US FDA-approved monoclonal antibodies targeting the EGF receptor (EGFR) include cetuximab and panitumumab. In this article, we discuss the clinical evidence concerning the use of monoclonal antibodies targeting the EGFR in the setting of advanced colorectal cancer and the emergence of predictive molecular biomarkers. In addition, we also consider the evidence surrounding the evolution of anti-EGFR-resistance mechanisms evoked by targeted anti-EGFR therapy and potential therapeutic strategies that may counteract resistant tumor growth.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Centre for Trials Research (CNTRR)
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	biomarkers, cetuximab, colorectal cancer, EGFR, monoclonal antibody, panitumumab
Publisher:	Informa Healthcare
ISSN:	1473-7140
Last Modified:	28 Oct 2022 08:38
URI:	https://orca.cardiff.ac.uk/id/eprint/71541

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item